Zhitong Finance App News, Wisdom Pharmaceutical (300149.SZ) issued an announcement. Beihai Ruizhi Venture Capital Co., Ltd. (hereinafter referred to as “Beihai Wisdom”), a wholly-owned subsidiary of the company, recently signed a “Wuhan Bainuo Jiatai Venture Capital Partnership (Limited Partnership)” with professional investment agency Shanghai Bainuo Private Equity Fund Management Co., Ltd. (hereinafter referred to as “Limited Partnership”) and other limited partners. Beihai Ruizhi, plans to use its own capital of 10 million yuan to Wuhan Bainuo Jiatai Venture Capital Partnership (Limited Partnership) Abbreviated as “Benoica “Thailand”) carried out a capital increase, accounting for 29.24% of the total capital pledged by the partnership.

The company's subsidiary is now investing in Guangzhou Keentai Biomedical Technology Co., Ltd. by participating in the investment fund. The invested company focuses on the original innovation of kinase inhibitors and is committed to developing FIC's innovative kinase small molecule anti-tumor drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.